Review Note
Last Update: 10/29/2024 06:05 PM
Current Deck: Genes and Development::Week 4::LE031 TMAs-SLD
Published
Fields:
Text
TTP management via (x3)
{{c1::plasma exchange - removes anti-ADAMTS13 antibody to replace ADAMTS13 enzyme in blood which is not inhibited (**cornerstone treatment) or plasma transfusion
immunosuppresion - steroids +/- rituximab (anti-CD20 inhibiting plasma cells which produces anti-ADAMTS13)
anti-vWF - caplacizumab so then platelets don't bind to vWF but then can have vWF disease of bleeding}}
{{c1::plasma exchange - removes anti-ADAMTS13 antibody to replace ADAMTS13 enzyme in blood which is not inhibited (**cornerstone treatment) or plasma transfusion
immunosuppresion - steroids +/- rituximab (anti-CD20 inhibiting plasma cells which produces anti-ADAMTS13)
anti-vWF - caplacizumab so then platelets don't bind to vWF but then can have vWF disease of bleeding}}
Back Extra
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: